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The objective of the present investigation is to formulate gastro retentive floating drug delivery systems (GRFDDS)
of propranolol HCl by central composite design and to study the effect of formulation variables on floating lag
time, D1hr (% drug release at 1 hr) and t90 (time required to release 90% of the drug). 3 factor central composite
design was employed for the development of GRFDDS containing novel semi synthetic polymer carboxymethyl
ethyl cellulose (CMEC) as a release retarding polymer. CMEC, sodium bicarbonate and Povidone concentrations
were included as independent variables. The tablets were prepared by direct compression method and were
evaluated for in vitro buoyancy and dissolution studies. From the polynomial model fitting statistical analysis, it was
confirmed that the response floating lag time and D1hr is suggested to quadratic model and t90 is suggested to
linear model. All the statistical formulations followed first order rate kinetics with non-Fickian diffusion mechanism.
The desirability function was used to optimize the response variables, each having a different target, and the
observed responses were highly agreed with experimental values. Statistically optimized formulation was
characterized by FTIR and DSC studies and found no interactions between drug and polymer. The results
demonstrate the feasibility of the model in the development of GRFDDS containing a propranolol HCl. Statistically
optimized formulation was evaluated for in vivo buoyancy studies in healthy humans for both fed and fasted
states. From the results, it was concluded that gastric residence time of the floating tablets were enhanced at fed
stage but not in fasted state.
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Drug delivery systems (DDS) are used for maximizing
the therapeutic index of the drug and also targeted for
reduction in the side effects. All over delivery systems
the oral drug delivery has become the mainstay of treat-
ment due to higher patient compliance and reduced
patient discomfort. Under certain circumstances prolong-
ing the gastric retention of a DDS is desirable for achiev-
ing greater therapeutic benefit of the drug [1]. For* Correspondence: venkatasrikanthmeka@gmail.com
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distribution, and reproduction in any mediumexample, drugs that are absorbed in the proximal part of
the gastrointestinal tract (GIT), and the drugs that are less
soluble or are degraded by the alkaline pH may benefit
from prolong gastric retention. In addition, for local and
sustained drug delivery to the stomach and the proximal
small intestine to treat certain conditions, prolonging
gastric retention of the therapeutic moiety may offer
numerous advantages including improved bioavailability,
therapeutic efficacy and possible reduction of the dose
size [2-4]. All over the retentive systems gastric floating
system for modulation of oral controlled drug delivery
was found to be great importance. Hence in the present
investigation effervescent floating systems were developed
for prolonging the gastric retention.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Experimental range and levels of the
independent variables in CMEC based formulations
Variables Range and levels
-1 0 +1
CMEC (mg) X1 200 240 280
% w/w Sodium bicarbonate concentration X2 5 10 15
% w/w povidone concentration X3 2.5 5 7.5
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selected as a model drug for the development of gastro
retentive floating drug delivery systems (GRFDDS). Pro-
pranolol is a nonselective beta-adrenergic receptor block-
ing agent possessing no other autonomic nervous system
activity used for the treatment of hypertension [5]. It is
highly lipophilic and almost completely absorbed after
oral administration. However, it undergoes high first-
pass metabolism by the liver and on average, only about
25% of propranolol reaches the systemic circulation [6].
Variability of propranolol bioavailability is depends upon
the secretory transporter P-glycoprotein (P-gp) located
on the epithelium cells. Although P-gp appears to be
distributed throughout the GIT, its levels are higher
in more distal regions (stomach < jejunum < colon).
Absorption through P-gp prolongs the drug exposure to
CYP3A4. The colocalization of P-gp and CYP3A4 in
the mature enterocytes and their overlapping substrate
specificity reasonably suggests that the function of these
two proteins may be synergistic and appear to be coor-
dinately regulated. Consequently, a greater proportion of
drug will be metabolized since the repetitive two-way
kinetics (drug excerption from the enterocytes into the
lumen via P-gp and reabsorption back into enterocytes)
will simply prolong the drug exposure to CYP3A4. This
mechanism not only limits the absorption of a wide var-
iety of drugs, including peptides, but also poses a threat
for potential drug interactions [7,8].
Based on previously published literature, applications
of gastro retentive drug delivery system (GRDDS) may
be suitable for the drugs insoluble in intestinal fluids
(acid soluble basic drugs), e.g., propranolol, metoprolol,
diazepam [8]. As discussed earlier, propranolol has short
half-life, high first-pass metabolism, presence of food
increases the bioavailability, P-gp plays important role in
the absorption, and the drug is acid-soluble basic drug
which make it suitable for GRDDS. A novel semi syn-
thetic polymer carboxy methyl ethyl cellulose (CMEC)
was used as release retarding polymer in the present
investigation. Till now there were no reports found on
CMEC as a release retarding polymer.
In the normal conventional optimization process, a
single independent variable is varied while all others are
kept constant at a specific set of conditions. It’s not pos-
sible to change more than one parameter at a time dur-
ing the formulation development. This method may lead
to unreliable results and improper conclusions besides
wastage of excipients due to the requirement of large
number of runs in achieving the desired goal. Response
surface methodology (RSM) is an alternative to over-
come this difficulty, which can be employed to optimize
the formulations with suitable experimental design. RSM
permits a deeper understanding of a process or product
and has important applications like optimization and inestablishing the robustness of that product. Central
composite designs are a progression from the factorial
designs which have been widely used in response-surface
modeling and optimization [9].
The objective of the present investigation is to develop
gastro retentive floating tablets (GRFT) of propranolol
HCl using central composite design. In this study CMEC
quantity, sodium bicarbonate concentration and Povi-
done concentration were selected as independent vari-
ables while floating lag time, D1hr and t90 were selected
as dependent variables. For this study Design Expert
software was used which gives information regarding
critical values for achieving the desired response and
also the possible interaction effects of selected independ-
ent variables on dependent variable.
Experimental
Materials
Propranolol HCl was provided by Dr Reddy’s Laboratories
Ltd (Hyderabad, India). CMEC, sodium bicarbonate, Povi-
done K 30 and magnesium stearate were obtained as gift
samples from Unichem Laboratories Ltd (Goa, India). All
other reagents and chemicals were of analytical grade.
Experimental design
RSM is an experimental design technique by which the
factors involved and their relative importance can be
assessed. In the present study, a central composite
design was employed containing 3 factors evaluated at
3 levels and experimental trials were performed at all
20 possible combinations. The levels of the 3 independ-
ent variables are shown in Table 1 and the formulation
variables evaluated include:
X1 =CMEC quantity in mg
X2 = % w/w Sodium bicarbonate concentration (% w/w
to the tablet weight)
X3 = % w/w Povidone concentration (% w/w to the
tablet weight)
The response variables include
Y1 = Floating lag time (sec)
Y2 =D1hr (% drug released at 1 hr)
Y3 = t90 (time required to release 90% of the drug)
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All the ingredients sufficient for a batch of 100 tablets
according to the formulae suggested by Design Expert
software shown in Table 2 were accurately weighed and
passed through the sieve 40. Propranolol HCl (80 mg)
was geometrically mixed with CMEC until a homoge-
neous blend was achieved. Povidone and sodium bicar-
bonate was added to the above mixture and mixed for
5 min in a polybag. Blend was lubricated with presifted
magnesium stearate (sieve 60) for 3 min in polybag. 1%
w/w of magnesium stearate was used in all the formula-
tions. The flow property of the final blend was found to
be good so final blend was directly compressed into
tablets on a 16-station rotary tablet punching machine
(M/s. Cad mach Machinery Co. Pvt., Ltd., India) using
9 mm round plain punches.Evaluation of GRFT
In vitro buoyancy studies
All the formulated floating tablets (n = 5) were subjected
to in vitro buoyancy studies. The floating lag time was
determined in one liter glass beaker containing 900 ml
of 0.1 N HCl [10]. The time required for the tablet to
rise to the surface and float was determined as floating









PCMECR 01 200 5
PCMECR 02 280 5
PCMECR 03 200 15
PCMECR 04 280 15
PCMECR 05 200 5
PCMECR 06 280 5
PCMECR 07 200 15
PCMECR 08 280 15
PCMECR 09 172.73 10
PCMECR 10 307.27 10
PCMECR 11 240 1.59
PCMECR 12 240 18.41
PCMECR 13 240 10 0
PCMECR 14 240 10 9
PCMECR 15 240 10
PCMECR 16 240 10
PCMECR 17 240 10
PCMECR 18 240 10
PCMECR 19 240 10
PCMECR 20 240 10In vitro dissolution studies
In vitro release of propranolol hydrochloride from the
prepared floating tablets was studied using USP XXIII
dissolution test apparatus (LABINDIA, Disso 2000)
employing the paddle stirrer (Apparatus-II). 900 ml of
0.1 N HCl was used as dissolution medium maintained
at a temperature of 37 ± 0.5 °C and the paddle was
rotated at 50 rpm [11]. Aliquots (5 ml each) were with-
drawn at predetermined time intervals by means of a
syringe fitted with 0.45 μm prefilter and immediately
replaced with 5 ml of fresh medium maintained at
37 ± 0.5 °C. The filtered samples were suitably diluted
with the dissolution medium wherever necessary and the
absorbance of the samples was measured at 289 nm and
results are given in Figure 1.
Release kinetics
Zero order release kinetics
Drug dissolution from dosage forms that do not disag-
gregate and release the drug slowly can be represented
by the equation:
Qt ¼ Q0 þ K0t
Where Qt is the amount of drug dissolved in time t,




Floating lag time (sec) D1hr (%) t90 (hr)
2.5 650 40.22 6.6
2.5 550 31.11 8
2.5 720 36.58 8.2
2.5 510 18.99 10.8
7.5 300 32.12 8
7.5 600 23.45 9.9
7.5 495 22.12 9.9
7.5 670 13.84 12.2
5 570 27.23 9
5 369 18.12 11
5 450 28.15 8.85
5 300 18.99 12
.80 310 34.59 9.8
.20 280 26.68 11.15
5 312 19.12 10.3
5 369 18.99 10.4
5 435 19.89 10.25
5 401 19.99 10.2
5 467 19.01 10.15
5 420 18.78 10
Figure 1 Dissolution Profile of GRFT formulations: A) PCMECR 01-05, B) PCMECR 06-10, C) PCMECR 11-15, D) PCMECR 16-20.
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expressed in units of concentration/time [12].
First order release kinetics
The release of the drug which followed first order kinet-




Where K is first order rate constant expressed in units
of time-1.
This equation can be modified as
log C ¼ logC0  Kt=2:303
Where C0 is the initial concentration of drug, k is the
first order rate constant, and t is the time. The data
obtained are plotted as log cumulative percentage of
drug remaining vs. time which would yield a straight line
with a slope of -K/2.303.Higuchi equation
It defines a linear dependence of the active fraction released
per unit of surface (Q) on the square root of time.
Q ¼ k2t1=2
Where, k2 is the release rate constant.
A plot of the fraction of drug released against square
root of time will be linear if the release obeys Higuchi
equation. This equation describes drug release as a diffu-
sion process based on the Fick’s law, square root time
dependent [14].
Korsmeyer-Peppas model
In order to define a model, which would represent a bet-
ter fit for the formulation, dissolution data was further
analyzed by Peppas and Korsmeyer equation (Power law).
Mt=M/ ¼ k:tn
Where, Mt is the amount of drug released at time t and
M/ is the amount released at time/, thus the Mt/M/ is
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constant and n is the diffusion exponent.
In this model, the value of n characterizes the release
mechanism of drug. For the case of cylindrical tablets,
0.45 = n corresponds to a Fickian diffusion mechanism,
0.45 < n < 0.89 to non-Fickian transport, n = 0.89 to Case
II (relaxation) transport, and n > 0.89 to super case II
transport [15].Hixson - Crowell model
Hixson and Crowell recognized that the particles regular
area is proportional to the cube root of its volume. They
derived the equation:
W 1=30 W 1=3t
 
¼ Kt
Where W0 is the initial amount of drug in the
pharmaceutical dosage form, Wt is the remaining
amount of drug in the pharmaceutical dosage form
at time t and K (kappa) is a constant incorporating the
surface – volume relation [16]. The equation describes
the release from systems where there is a change in
surface area and diameter of particles or tablets.
Correlation coefficients and release rate kinetics are
shown in the Table 3.Statistical analysis of the data and optimization
Polynomial models including linear, interaction and
quadratic terms were generated for all the response vari-
ables using Design Expert software. The best fitting
model was selected based on the comparisons of several
statically parameters including the coefficient of vari-
ation (CV), the coefficient of determination (R2),
adjusted coefficient of determination (adjusted R2) and
the predicted residual sum of square (PRESS) provided
by Design Expert software. In addition, statistical ana-
lysis like analysis of variance (ANOVA) to identify
significant effect of factors on response, regression coef-
ficients, F test and P value were also calculated with the
software. The results are given in Table 4-5.
The relationship between the dependent and inde-
pendent variables was further elucidated by using re-
sponse surface plots (Figure 2-3). These plots are useful
in the study of the effects of factors on the response
at one time and predict the responses of dependent
variables at the intermediate levels of independent vari-
ables. Subsequently, a numerical optimization technique
by the desirability approach (Figure 4) and graphical
optimization technique by the overlay plot (Figure 4)
were used to generate the new formulations with the
desired responses.Validation of the experimental design
To validate the chosen experimental design, the result-
ant experimental values of the responses were quantita-
tively compared with those of predicted values and %
relative error was calculated by the following equation;




Fourier transformation-infrared spectroscopy (FTIR)
FTIR is used to identify the drug excipient interaction.
FTIR studies were performed on drug, polymer and sta-
tistically optimized formulation. Samples were analyzed
by potassium bromide pellet method in an IR spec-
trophotometer (Shimadzu, FTIR 8700) in the region
between 3500-500 cm-1.
Differential scanning calorimetry (DSC)
Differential Scanning Calorimetric analysis of drug,
polymer and statistically optimized formulation were
done using Differential Scanning Calorimeter (Mettler
Toledo Star SW 8.10, Model no: DSC 822). In this
process about 8-10 mg of the samples were weighed in
aluminum pan and were heated under nitrogen atmos-
phere from 5 °C to 250 °C.
In vivo buoyancy studies
To confirm the spatial and temporary placement of
floating drug delivery system, a variety of techniques
have been used like string technique, endoscopy and
gamma scintigraphy [17-20]. Of these techniques,
X-ray technique was used to determine the gastric
residence time of the tablets. In the present investiga-
tion X-ray studies were conducted for the evaluation
of intragastric floating behavior of the statistically opti-
mized GRFT of propranolol HCl both in fasted and
fed states.
The in vivo X-ray evaluation of floating ability studies
were carried out by administering GRFT of propranolol
HCl containing barium sulfate (BaSO4) in humans in
fasted and fed state.
Two healthy male subjects of mean age 25 ± 2 yrs
(ranging from 23 to 27), mean weight 68 ± 10 Kg
(ranging from 58 to 78 kg) and a mean height of
170 ± 5 cm (ranging from 165 to 175 cm) participated in
this study. The volunteers were judged healthy on the
basis of their previous medical history, physical examin-
ation and routine laboratory tests. Both subjects were
presented with full details of the investigation, verbally
and in written form, prior to providing written informed
consent and the study was conducted under the guid-
ance of radiologist. The study was approved from an
Table 3 Correlation coefficient values and release kinetics of GRFT
Formulation Zero order First order Higuchi Hixson Crowell Peppas
Ko r K1 r r r n r
PCMECR 01 8.8464 0.9128 0.3922 0.9764 0.9856 0.9848 0.3821 0.9837
PCMECR 02 8.9460 0.9311 0.2738 0.9912 0.9889 0.9786 0.4640 0.9687
PCMECR 03 8.6046 0.9276 0.2519 0.9872 0.9893 0.9593 0.4007 0.9822
PCMECR 04 6.8619 0.9641 0.2158 0.9860 0.9955 0.9953 0.5905 0.9841
PCMECR 05 9.0042 0.9211 0.2886 0.9908 0.9835 0.9745 0.4530 0.9644
PCMECR 06 7.7720 0.9623 0.2174 0.9955 0.9969 0.9937 0.5565 0.9910
PCMECR 07 7.7709 0.9676 0.2119 0.9916 0.9972 0.9938 0.5791 0.9920
PCMECR 08 6.1913 0.9695 0.2027 0.9728 0.9950 0.9947 0.6678 0.9827
PCMECR 09 7.7972 0.9597 0.2660 0.9778 0.9981 0.9930 0.5213 0.9966
PCMECR 10 6.8746 0.9658 0.2119 0.9831 0.9957 0.9947 0.6067 0.9844
PCMECR 11 7.7522 0.9528 0.2840 0.9709 0.9968 0.9908 0.4961 0.9926
PCMECR 12 6.7415 0.9679 0.1835 0.9959 0.9965 0.9958 0.5917 0.9896
PCMECR 13 7.0102 0.9243 0.2830 0.9463 0.9881 0.9807 0.3870 0.9845
PCMECR 14 6.5653 0.9549 0.2004 0.9822 0.9942 0.9893 0.4732 0.9927
PCMECR 15 7.8594 0.9646 0.2036 0.9965 0.9943 0.9564 0.6207 0.9826
PCMECR 16 7.8342 0.9659 0.2929 0.9975 0.9942 0.9837 0.6264 0.9854
PCMECR 17 7.8163 0.9655 0.2022 0.9967 0.9950 0.9801 0.6101 0.9869
PCMECR 18 7.8216 0.9644 0.2063 0.9957 0.9951 0.9749 0.6073 0.9852
PCMECR 19 7.8945 0.9643 0.2096 0.9958 0.9944 0.9931 0.6246 0.9820
PCMECR 20 7.9658 0.9637 0.2169 0.9950 0.9941 0.9934 0.6288 0.9798
Srikanth Meka et al. DARU Journal of Pharmaceutical Sciences 2012, 20:21 Page 6 of 12
http://www.darujps.com/content/20/1/21independent Institutional Ethics Committee of Andhra
University, Visakhapatnam (India).
The statistically optimized GRFT of propranolol HCl
was administered to the two volunteers, one under
fasted and another one under fed states.Table 4 Summary of ANOVA results in analyzing lack of fit (LOF
Parameters Sum of squares df Mean Square
Floating lag time (Qua
Model 171694 9 19077.11
Residual 170028 10 17002.78
Lack of Fit 155211 5 31042.10
Pure Error 14817 5 2963.4667
D1hr (Quadratic
Model 942.28 9 104.6973
Residual 65.26 10 6.5265
Lack of Fit 63.96 5 12.7915
Pure Error 1.31 5 0.2614
t90 (Linear m
Model 29.439 3 9.812
Residual 7.377 16 0.461
Lack of Fit 7.2837 11 0.662
Pure Error 0.0933 5.0000 0.0181. Fasted state: The subject was fasted overnight and
then swallowed the gastric floating tablet with 200 ml
of water. No food was allowed up to 3 hrs of dosing.
Subject was not allowed to lay down for sleeping.
Every one hour a glass of water (200 ml) was given.) and pure error
F value p value Prob> F Remark
dratic model)
1.122 0.4269 Not significant
10.47 0.0111 significant
model)
16.04 < 0.0001 significant
48.93 0.0003 significant
odel)
21.28 < 0.0001 significant
35.47 0.0005 significant
Table 5 Statistical parameters
Parameters Floating lag time D1hr t90
Std. Dev. 130.39 2.555 0.68
Mean 458.90 24.399 9.84
C.V. % 28.41 10.471 6.90
PRESS 1195095.90 502.960 12.95
R-Squared 0.5024 0.9352 0.7996
Adj R-Squared 0.0546 0.8769 0.7621
Pred R-Squared -2.4973 0.5008 0.6484
Adeq Precision 3.4934 12.842 16.4605
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the morning given a high calorie-high fat breakfast
with a total calorie value of approximately 900 Cal.
The floating tablet was administered with 200 ml of
water after half an hour of the breakfast. The subject
was not allowed to eat anything up to 6 hrs but given
a glass of water (200 ml) every hour.
Preparation of GRFT for in vivo studies
Optimized GRFT of propranolol HCl containing barium
sulfate (PCMECRsoB) for in vivo X-ray evaluation were
prepared by direct compression method. The amount of
propranolol HCl was reduced to 40 mg for incorporating
the barium sulfate (40 mg) as radio opaque substance to
maintain the constant weight of the tablet. Propranolol
HCl (40 mg) was geometrically mixed with CMEC until
a homogeneous blend was achieved. Barium sulfate
(40 mg), Povidone and sodium bicarbonate were added
to the above blend, mixed and lubricated with magne-
sium stearate (1%w/w). Final blend was directly com-
pressed into tablets on a 16-station rotary tablet
punching machine (M/s. Cad mach Machinery Co Pvt
Ltd. India) using 9 mm round plain punches at hardness
of 4-6 kg/cm2.
Results and discussion
All the floating tablets were passed physicochemical
tests like weight variation, assay and friability. Floating
lag times of all the formulations were within the rangeFigure 2 Response surface plot for (A) the effect of CMEC and sodium
povidone concentrations on D1hr (C) effect of sodium bicarbonate anof 280 to 720 sec (Table 2). As the concentration of so-
dium bicarbonate increases, the floating lag time found
to be decreased.
The cumulative percent drug releases from GRFDDS
prepared by central composite design with CMEC are
shown in the Figure 1. From the results, it was observed
that as the concentration of polymer increased along with
concentration of sodium bicarbonate the drug release was
retarded. This may be due to increased intensity of air
pockets surrounding the jellified surface of the tablet.
Increase in the concentration of the sodium bicarbonate
at constant polymer concentration also retarded the drug
release due to high intensity of the carbon dioxide gas
pockets. Drug retardation was directly proportional to the
concentration of Povidone which may be due to the for-
mation of strong compactness between the particles [21].
All CMEC based formulations followed first order rate
constant with non Fickian diffusion mechanism. (Table 3).
The responses of the floating tablets were fitted to lin-
ear, interaction and quadratic model using Design Expert
software. As suggested by the software the responses
floating lag time, and D1hr is suggested to quadratic
model and t90 is suggested to linear model (Table 4).
Data analysis
By using semi synthetic polymer CMEC, 20 batches of for-
mulations within the experimental design were prepared
to obtain floating tablets which were evaluated for their
floating lag time, D1hr and t90. From the ANOVA data, the
F value for the floating lag time was found to be 1.12
which indicates that the model is non-significant, whereas
for other responses D1hr and t90 the F value was found to
be 16.04 and 21.28 respectively which indicates that both
models are significant. The values of Prob > F less than
0.05 for all the responses except floating lag time are indi-
cating that the models are significant. The response float-
ing lag time exhibited Prob > F value 0.4269, which
indicating model was not significant (Table 4). In the re-
sponse observation for D1hr A, B, C, B^2 and C^2, for t90
A, B and C was found to be significant model terms. For
floating lag time no significant model terms were found
(A: CMEC, B: Sodium bicarbonate, C: Povidone). The lackbicarbonate concentrations on D1hr (B) effect of CMEC and
d povidone concentrations on D1hr.
Figure 3 Response surface plot for (A) the effect of CMEC and sodium bicarbonate concentrations on t90.
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to be 0.0111, 0.0003 and 0.0005 respectively implies that
the lack of fit is significant. Similarly ‘R- squared’ value was
also calculated for all responses. The ideal value is nearer
to zero. ‘R- Squared’ value in the present model is near to
zero which indicates towards a good model. In all the cases
‘Pred R squared’ values are in reasonable agreement with
the ‘Adj R squared’ values except floating lag time (0.8769
& 0.5008 for D1hr and 0.7621 & 0.6484 for t90). A negative
‘Pred R squared’ was observed for the floating lag time
response which implies that the overall mean is a better
predictor of this response than current model. In all the
case ‘Adeq Precision’ values are in the range of 12 – 17
except floating lag time which indicates an adequate signal
and the model can be used to navigate the design space.
For floating lag time ‘Adeq Precision’ was found to be 3.49
which indicates an inadequate signal and we should not
used this model to navigate the design space (Table 5).
Even though lack of fit was significant for all the variables,
the model was preceded further because of the positive
results obtained with other parameters such as F value,
values of Prob > F, ‘R- squared’, Pred R squared’ and ‘Adj RFigure 4 Desirability plot and Overlay plot for optimization of gastrosquared’ for D1hr and t90 responses. Hence in the present
investigation only D1hr and t90 responses were taken
as dependent variables and optimization was proceeding
with these parameters.
The application of response surface methodology yielded
the following regression equations which are an empirical
relationship between the logarithmic values of floating lag
time, D1hr and t90. Test variables in coded units:
Floating lag time ¼ 394:75 12:67  Aþ 3:13  B
30:42  C 29:37  A  B
þ98:13  A  Cþ 29:38  B  C
þ63:02  A2 þ 29:61  B2 þ 1:32  C2
D1hr ¼ þ19:25 4:32  A 3:72  B 3:56  C
1:01  A  Bþ 1:22  A  C 0:48  B  C
þ1:47  A2 þ 1:78  B2 þ 4:28  C2
t90 ¼ 9:83þ 0:85  Aþ 1:02  Bþ 0:63  C
The contour and response surface plots for the all
responses of all the formulation factors are shown inretentive floating tablets of propranolol HCl.
Figure 5 FTIR spectra of propranolol HCl, CMEC and PCMECRso.
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surface as a function of two factors at a time, holding all
other factors at fixed levels, are more helpful in under-
standing both the main and the interaction effects of
these two factors.
Optimization
To optimize all the responses with different targets, a
multi criteria decision approach like a numerical
optimization technique by the desirability function and
graphical optimization technique by the overlay plot
were used (Figure 4). The optimized formulation was
obtained by applying constraints on dependent variable
responses and independent variables.Figure 6 DSC thermogram of a) propranolol HCl, b) CMEC and c) PCMOptimized formulation was selected based on the cri-
teria of less than 20% of the drug release at 1 hr (fixed
by USP dissolution conditions [11]) and 90% of the drug
released in between 10 to 11 hrs. Floating lag time was
omitted in the optimization process as per the previous
discussion. These constrains are common for all the
formulations. The recommended concentrations of the
independent variables were calculated by the Design
Expert software from the above plots which has the
highest desirability near to 1.0.
The optimum values of selected variables obtained by
using Design Expert software was 248.88 mg of CMEC,
9.66% of sodium bicarbonate and 5.18% of Povidone for
the development of GRFT of propranolol HCl.ECRso.
Table 6 In vivo residence time of the optimized GRFT of
propranolol HCl containing barium sulfate (PCMECRsoB)
Time
(hrs)
Position of the tablet in GIT
Fed state Fasted state
0.5 Stomach Stomach
2 Stomach Stomach
4 Stomach Small intestine
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The optimized formulation fulfilled all the criteria of
physicochemical properties. In vitro buoyancy and dis-
solution studies were carried out on the prepared opti-
mized formulations for verification of the theoretical
prediction. Observed responses and predicted values for
D1hr and t90 was found to be 17.21%, 10.3 hrs and
18.43%, 10 hrs respectively. The % relative error between
the predicted values and experimental values of each
response was calculated and the values were found to
be 2.55% and 3.0% for D1hr and t90 respectively. From the
results, it was concluded that these experimental findings
are in close agreement with the model predictions which
confirmed the predictability and validity of the model.
Drug interaction studies
Fourier transformation-infrared spectroscopy (FTIR)
The FTIR spectrum of propranolol HCl, CMEC and
Optimized formulation are shown in Figure 5. Propran-
olol HCl showed characteristic secondary amine –N–H
stretch at 3280 cm-1, C-H stretch at 2964 cm-1, Aryl C =
C stretch at 1579 cm-1, Aryl 0-CH2 asymmetric stretch
at 1240 cm-1, Aryl 0-CH2 symmetric stretch at 1030 cm
-1
and the peak at 798 cm-1 due to alpha- substituted naph-
thalene [22].
The FTIR spectrum of CMEC showed the characteris-
tic alcoholic –OH stretch at 3476 cm-1, C-H stretch atFigure 7 X- ray photographs of gastric floating tablets of PCMECRsoB
(b) 2 hrs (c) 4 hrs (d) 6 hrs.2976 cm-1, -C = O stretch at 1761 cm-1 and -C-O-C
asymmetric stretch at 1378 cm-1.
Statistically optimized CMEC based formulation
(PCMECRso) showed all the characteristic peaks of pro-
pranolol HCl with minor shifts in its FTIR spectrum. This
spectrum showed secondary amine –N–H stretch at
3280 cm-1, C-H stretch at 2974 cm-1, Aryl C = C stretch at
1579 cm-1, Aryl 0-CH2 asymmetric stretch at 1241 cm
-1,
Aryl 0-CH2 symmetric stretch at 1031 cm
-1 and the peak
at 797 cm-1 due to alpha- substituted naphthalene.
Differential scanning calorimetry
DSC thermogram of propranolol HCl, CMEC and
PCMECRso are shown in the Figure 6. The DSC
thermogram of CMEC showed a sharp endothermic
peak at 183.5 °C that corresponds its melting point.
From the results, it was observed that the thermogram
of statistical optimized formulation PCMECRso showed
sharp endothermic peaks at 163.2 °C and 183.1 °C repre-
sents drug and polymer respectively, which indicated that
slight decrease in the energy change of melting endo-
therm, which confirms minor extent of reduction in the
crystallinity of the drug but not a significant reduction.
The absence of any changes in the FTIR spectra and
DSC thermogram for the selected formulation indicated
no chemical interaction between the CMEC and drug.
In vivo buoyancy studies
This study was aimed to examine whether the floating
tablet system could buoyant and retain in the stomach.
A radiological method was adopted to monitor the
developed gastro retentive floating tablets in the gastric
region of humans in different feeding conditions. The
GRFT remained buoyant on gastric content under both
fasted and fed states in volunteers participated in the
present study. However, a difference in floating and
gastric retention time was obeyed according to the feed-
ing conditions given in Table 6.
In the fasted state, the floating tablets were observed
to be buoyant on the gastric fluid up to at 2 hr as showncontaining propranolol HCl under fasted state after (a) 0.5 hrs
Figure 8 X- ray photographs of gastric floating tablets of PCMECRsoB containing propranolol HCl under fed state after (a) 0.5 hrs (b) 2 hrs
(c) 4 hrs (d) 6 hrs (e) 8 hrs.
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http://www.darujps.com/content/20/1/21in Figure 7 (a&b) and were observed in the small intes-
tine after 4 hrs as shown in Figure 7 (c) and was disap-
peared at 6th hr as shown in Figure 7 (d). Therefore, in
such condition, the floating property did not enhance
gastric retention time (GRT). The rapid emptying was
attributed to periods of strong contractile activity, which
occur under fasting conditions every 1.5 to 2 hrs, and ef-
fectively sweep undigested material from the stomach
[20,23]. As a result of this activity, dosage form adminis-
tered to fasted subjects could be emptied as rapidly as
within an hour or two, depending on the presence of the
strong motor induced contractile activity.
In the fed state after the high calorie high fat breakfast,
the GRFT was observed to be buoyant on the gastric
contents up to 6 hrs after administration as shown in
Figure 8 (a) at 0.5 hrs, 8 (b) at 2 hrs, 8 (c) at 4 hrs, 8 (d)
at 6 hrs and disappeared at 8th hr shown in Figure 8 (e).
Therefore, in the fed condition, the floating system
showed a GRT prolonged by about 5 to 6 hrs over the
fasted state.
The evaluation of the GRFT of propranolol HCl intra-
gastric behavior in humans, showed the actual floatabil-
ity of the tablet on the gastric content.
This study has demonstrated that in the fasted state
under the influence of strong motor activity (the migrat-
ing myoelectric complex), there was no enhancement of
GRT of gastro retentive floating tablet, where as there
was a prolonged GRT of approximately 6 hrs in a
fed state.
Conclusion
Thus the present study clearly indicated the applicability
of the statistical optimization techniques for the predic-
tion of the optimized concentrations of the excipients
that influence the product parameters. These theoretical
predictions can be verified for their experimental success
as in the present case. The statistical optimization
reduces the number of experiments to be carried for
obtaining formulation with desired properties. More-
over the optimization is also useful in reducing the
concentrations of the excipients to their optimum levelsavoiding unnecessary wastage of excipients and thereby
reducing the cost of the final product. The intragastric
behavior of statistically optimized GRFT of propranolol
HCl in humans, showed the floatability of the tablet on
the gastric content. In vivo evaluation demonstrated
no enhancement of GRT of gastro retentive floating
tablet in fasted state, where as there was a prolonged
GRT of approximately 6 hrs in the fed state. From the
results, it is concluded that CMEC is novel semi syn-
thetic polymer suitable for the development of GRFT of
propranolol HCl.
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